Drug target landscape expands to 686 biomolecules hit by 1,702 approved drugs
A 25-year review maps how genomics, proteomics and new drug modalities have widened the set of targets through which medicines work.
Summary
This Nature Reviews Drug Discovery article maps how the set of biological targets for medicines has changed over the past 25 years. Advances in genetics, genomics, proteomics, automation and data science, along with therapeutic modalities beyond classic small molecules and natural-product derivatives, have broadened what can be treated. The authors report that drugs now act through 686 biomolecules, modulated by 1,702 drugs. They quantify trends in the number and type of targets and discuss which trends they expect to continue or shift as druggability evolves with new modalities. Only the abstract was available, so details such as target classes, modality breakdowns and specific disease areas could not be assessed. The review is a landscape analysis, not a clinical study, and several authors disclose industry ties.
Detailed Summary
Why it matters: Drug discovery has changed substantially since 2000. Knowing which biological targets medicines act on, and how that set is growing, helps researchers, clinicians and investors see where therapeutic progress is happening, including for diseases that once had no pharmacological options. This is relevant to longevity medicine, which depends on a broad toolkit of druggable pathways.
What was reviewed: The authors map and quantify changes in the drug target landscape over roughly 25 years. They examine trends in the number and type of targets through which drugs exert therapeutic effects, drawing on the influence of genetics, genomics, proteomics, automation, data science and newer therapeutic modalities beyond synthetic small molecules and natural-product derivatives.
Key results: According to the abstract, the current landscape includes 686 biomolecules modulated by 1,702 drugs. The authors describe an expansion of the target space that has enabled treatment advances across many diseases, including some previously lacking pharmacotherapies.
Implications: The authors discuss trends they believe will continue or change as druggability evolves with emerging modalities. This suggests that targets once considered undruggable may become accessible, widening options in areas such as aging-related disease.
Caveats: Only the abstract was available, so the data sources, definitions of a target, modality breakdowns and specific forecasts could not be evaluated. The work is a narrative review and mapping exercise, not a trial, and forward-looking statements reflect author opinion. Several authors disclose financial ties to pharmaceutical and AI drug discovery companies.
Key Findings
- Drugs now exert therapeutic effects through 686 biomolecular targets.
- These targets are modulated by 1,702 drugs, per the review's quantification.
- The analysis covers trends in target number and type over the past 25 years.
- Genomics, proteomics, automation and data science drove expansion of the target landscape.
- New therapeutic modalities beyond small molecules are expected to keep changing target druggability.
Methodology
This is a narrative review that maps and quantifies changes in drug targets over about 25 years. Based on the abstract, it catalogs targets and the drugs that modulate them and discusses expected trends. Specific data sources and curation criteria were not available.
Study Limitations
Only the abstract was reviewed, so methods, target classifications and modality-specific details are unknown. As a review, it includes author opinion on future trends, and several authors report financial interests in pharma and AI drug discovery firms.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: